Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07544628 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of Navlimetostat Tablet Formulations
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT07544628 is a Phase 1 study that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 64 participants.
The verdict
NCT07544628, a Phase 1 study, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This study aims to compare the PK of Navlimetostat after administration of a wet-granulation tablet versus the dry-granulation tablet formulation in healthy adult female
Interventions
- DRUG Navlimetostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2026-04-27 |
| Est. Completion | 2026-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07544628
The ClinicalTrials.gov registry entry for NCT07544628 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Navlimetostat is the first listed.
NCT07544628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07544628 about?
NCT07544628 is a clinical study titled "A Phase 1 Study of Navlimetostat Tablet Formulations". This study aims to compare the PK of Navlimetostat after administration of a wet-granulation tablet versus the dry-granulation tablet formulation in healthy adult female
What is the current status of trial NCT07544628?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2026-04-27. Estimated completion is 2026-10-15.
What interventions are being tested in trial NCT07544628?
The interventions under investigation include: Navlimetostat (DRUG).
Who is sponsoring clinical trial NCT07544628?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.